Completed
PHASE2
INTERVENTIONAL
NCT01491971
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.
Interventions
Name:
Degarelix
Type:
DRUG
Description:
Primary Outcomes
Measure:
Plasma degarelix PK profile (blood sample analysis): measured by (Cmax, AUC, Tmax)
TimeFrame:
Day 0-28 and at Day 112-140
Description:
Measure:
Trough plasma levels (blood sample analysis)
TimeFrame:
Day 28, 56, 84, 112, 140, 168 and 196
Description:
Actual levels prior to dosing
Trial Information
NCT ID
NCT01491971
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Ferring Pharmaceuticals
Last Updated
December 15, 2025